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expression
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Abstract
We recently reported one interesting case showing mutation-free c-KIT proto-oncogene overexpression and
paradoxical hypermethylation in 54 cases of primary squamous cell carcinoma of uterine cervix (SCC). However,
its molecular mechanisms still remain unknown. We propose the hypothesis that increased methylation at the CpG
islands on the promoter near the first exon region might interfere with the binding of CTCF repressor with c-KIT
promoter that regulates c-KIT proto-oncogene expression in such case. Further studies focusing on the status of
epigenetic modifications of mutation-free c-KIT (+) tumors are encouraged.
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Background
Epigenetic modifications may occur that result in changes
in gene expression. Epigenomes represent an attractive
therapeutic target. Current use of agents targeting epigen-
etic changes has become an interesting topic in cancer
research. Additional evidence suggests that DNA methyl-
transferase inhibitors may serve as efficient chemo- and
radiosensitizers in solid tumors [1]. Furthermore, tight
association of DNA methylation and silencing of gene
expression have been already established. Hypomethyla-
tion is the mechanism for ectopic oncogene activation
whereas hypermethylation is the mechanism for tumor
suppressor gene inactivation [2, 3]. In 54 cases of primary
squamous cell carcinoma of uterine cervix (SCC) of
uterine cervix, we recently demonstrated one case show-
ing mutation-free, over-expression and paradoxical hyper-
methylation of the c-KIT proto-oncogene [4–6]. Within
this afore-mentioned unusual case (no. 26), the DNA
methylation ratio of the promoter near the first exon re-
gion in c-KIT (+) tumor area (26 T) was higher than that
in adjacent c-KIT (−) non-tumor cervical epithelium
(26 N). On the other hand, when comparing two cases
with different c-KIT expression (no. 12 and no. 26), the
DNA methylation ratio in the c-KIT (+) tumor area
(26 T) was higher than that in another randomly selected
c-KIT (−) tumor area (12 T) and adjacent c-KIT (−) non-
tumor cervical epithelium (12 N) [4]. However, the
molecular mechanisms for this difference still remain
unknown.
The analysis of results from MethHC, a database of
DNA methylation and mRNA expression profiles in
human cancer showed that hyper-methylation in the pro-
moter region of c-KIT proto-oncogene induced the down-
regulation of gene expression in most cancer tissues such
as colon adenocarcinoma. Conversely, the increased DNA
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methylation ratio in upstream 500 bps of promoter re-
gion enhanced the expression of c-KIT proto-oncogene
in uterine corpus endometrial carcinoma [7, 8]. This
phenomenon is similar to our previous findings in the
unusual uterine cervix carcinoma case [4]. Intriguingly,
this is counter to the current understanding that aber-
rant DNA methylation tends to silencing of genes.
Transcriptional repressor CTCF also known as 11-zinc
finger protein or CCCTC-binding factor is a transcription
factor in humans that is encoded by the CTCF gene [9].
Recent references demonstrated that absent or un-bound
CTCF was associated with increased DNA methylation at
a gene promoter in either normal or cancer cells [10, 11].
In addition, Lai et al. demonstrated that DNA methylation
can activate the expression of CTCF-silenced oncogene
BCL6 via blocking the binding of CTCF repressor to the
first intron region [12]. Conversely, inhibition of DNA
methyltransferase decreases BCL6 transcription due to
the binding of CTCF to DNA in the methylation-sensitive
region. Our previous studies and cumulative references
suggested that increased methylation at the CpG islands,
which are found on the promoter near the first exon re-
gion, might interfere with the binding of CTCF repressor
with c-KIT promoter that regulates c-KIT proto-oncogene
expression in such a case.
Presentation of the hypothesis
In this report, we propose a hypothesis for the “paradox”
phenomenon between aberrant methylation and expres-
sion of c-KIT proto-oncogene in SCC uterine cervix.
Increased methylation at the CpG islands of c-KIT pro-
moter might interfere with the binding of certain repres-
sor proteins such as CTCF transcriptional repressor (TR)
that regulate c-KIT proto-oncogene expression. In gen-
eral, CTCF binds to the CTCF-binding site on the pro-
moter near the first exon region, as shown in Fig. 1.
Subsequently, the hypo-methylation of the promoter re-
gion results in the silencing of the c-KIT proto-oncogene
expression through interference with other transcription
factors (TFs) to bind the promoter region. When CTCF-
binding sites are partly methylated during tumorigenesis
in uterine cervix, CTCF is unable to bind the methylated
promoter region and loses the repressive function. There-
fore, the TFs can smoothly bind to the promoter region
and drive c-KIT proto-oncogene expression. In addition,
when the CpG islands of the c-KIT promoter region are
hyper-methylated, CTCF and TFs both are unable to bind
to their binding sites and then the c-KIT proto-oncogene
is silenced again (Fig. 1).
Testing the hypothesis
(1)To test this hypothesis, we must first sequence
the methylation status of full length CpG islands
of c-KIT proto-oncogene on promoter regions in
several candidate cervical cancer cells by using
bisulfide sequencing or pyrosequencing, and then
correlate DNA methylation with the expression
levels of c-KIT proto-oncogene in these cells. For
our testing cell model, we will select the cells that
are both hypermethylated at the CpG islands on
the promoter near the first exon region and also
express higher levels of c-KIT mRNA measured by
quantitative RT-PCR.
(2)Second, we will treat the cells with the DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine
Fig. 1 The analysis of the c-KIT proto-oncogene promoter region and the prediction of CTCF binding sites. The c-KIT proto-oncogene contains a
long CpG island including promoter, first exon and first region ranging from −736 bp to 1224 bp. The CpG island region contains at least three
putative transcriptional repressor CTCF binding sites predicted by the CTCFBSDB 2.0 database [13–15]. The methylation-specific (MS) PCR primer
sets were designed to be located in the region between the first Exon and first intron by using MethPrimer software [16, 17]. The blue box indicates
the putative CTCF binding sites. *1 indicates the transcription start site of c-KIT proto-oncogene
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(5-Aza-C), and test the change in expression level of
the c-KIT proto-oncogene by quantitative RT-PCR.
We hope to find that the expression of c-KIT
proto-oncogene is related to the methylation of
CpG islands, which are found on the promoter
near the first exon region containing three putative
CTCF-binding sites.
(3)Third, we will analyze the amount of CTCF
binding to the promoter region with three
putative CTCF-binding sites by using a chromatin
immunoprecipitation assay with specific primers
to test cells treated with various concentration of
5-Aza-C. We will observe that the amount of
CTCF binding to the promoter region increases
with greater doses of 5-Aza-C. This will means that
de-methylation on the promoter region enhances the
binding activity of CTCF on the promoter region
with three putative CTCF-binding sites.
(4)Fourth, we will intensify or diminish the expression
of CTCF and then measure the expression of c-KIT
proto-oncogene to prove whether CTFC could
directly bind to the promoter region to regulate the
expression of c-KIT proto-oncogene.
(5)Finally, we will assay the DNA methylation status
and gene expression of c-KIT proto-oncogene in
the large-scale clinical samples, and correlate the
relationship between DNA methylation status and
gene expression in SCC of the uterine cervix.
Implications of the hypothesis
We propose the hypothesis that increased methylation at
the CpG islands might interfere with the binding of the
CTCF repressor with the c-KIT promoter which regulates
c-KIT proto-oncogene expression in c-KIT (+) squamous
cell carcinoma of uterine cervix. The paradoxical hyper-
methylation of the c-KIT promoter here suggests that
therapeutic strategies using demethylating drugs could be
effective against c-KIT (+) SCC of uterine cervix. Even
though the low frequency (1/54 = 1.86 %) of mutation-
free c-KIT proto-oncogene over-expression and aberrant
methylation suggests that our result may not be represen-
tative of a larger population, further studies that focus on
the status of epigenetic modifications of mutation-free c-
KIT (+) tumors are still merited to clarify this point of
view.
Abbreviation
SCC: squamous cell carcinoma of uterine cervix.
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